CVS Health reported a sharp increase in second-quarter earnings and raised its full-year financial outlook, but the stock has struggled to sustain momentum after the results. The company posted revenue of $106.1 billion, up 7.3% year over year, while earnings per share rose to $2.31, up 188%, and shares have since declined more than 12% over the past month.
Investors’ reaction appears to reflect a trade-off: stronger top-line and profitability metrics on the one hand, and lingering concerns about margin pressure in its pharmacy benefits manager business and broader headwinds in government-related drug pricing programs on the other.
Key takeaways
- Price move: CVS shares are down more than 12% over the past month and are up 17% year to date.
- Catalyst: Second-quarter results showed revenue growth of 7.3% and EPS of $2.31, up 188% year over year.
- Guidance: CVS increased 2026 revenue expectations to at least $414 billion and raised expected yearly EPS to a range of $6.84 to $7.04.
- Key implication: Persistent worries about PBM margins and revenue headwinds tied to the 340B drug pricing program remain a central overhang for investors.
What drove the move
CVS’s latest quarter underscored improvements across multiple parts of its integrated model. The company reported revenue of $106.1 billion for the quarter ended in its second quarter, reflecting year-over-year growth of 7.3%. Earnings per share rose to $2.31, a significant increase of 188% compared with the prior-year period.
Beyond the quarterly figures, management also updated forward expectations. CVS lifted its 2026 revenue guidance to at least $414 billion, up from earlier estimates of at least $405 billion. It also raised its full-year EPS outlook to between $6.84 and $7.04, compared with earlier guidance of $6.24 to $6.44.
CVS also forecast 2026 revenue expectations that track upward, signaling management confidence in demand and execution across its retail pharmacy, clinical services, insurance, and pharmacy benefits segments.
Why the stock hasn’t kept climbing
Despite the earnings beat and upgraded guidance, investors appear to be focusing on several risks that could limit profitability over time—especially in the company’s pharmacy benefits manager business.
According to commentary management provided during its earnings call, investors should pay attention to membership declines at Caremark expected in 2027. The company also cited ongoing revenue headwinds in the 340B drug pricing program, attributing pressure to manufacturer-imposed restrictions that affect how certain drugs are priced and reimbursed.
Additionally, CVS’s PBM operation faces heightened regulatory scrutiny. The report said increased Federal Trade Commission oversight contributed to an antitrust settlement with Caremark in July. The same update noted proposed legislation aimed at improving pricing transparency in PBM arrangements, a development that could affect how future contracts are structured and how pricing power is distributed across the healthcare supply chain.
Investors also weighed progress within CVS’s insurance segment. The report said the company’s health benefits segment—Aetna—saw its medical benefit ratio improve to 87.4%. However, the market appears unconvinced that medical cost trends will remain contained given broader inflation pressures affecting healthcare utilization across the industry.
Market reaction and what investors are watching next
CVS’s share performance suggests the market is balancing near-term execution against structural uncertainty in reimbursement economics and PBM regulation. Even with stronger earnings and higher guidance, concerns over margins in the PBM segment and the pace of membership dynamics at Caremark appear to be key factors influencing investor sentiment.
Looking ahead, investors are likely to watch for further clarity on several fronts: the trajectory of Caremark membership trends, updates on how 340B pricing headwinds evolve, and any regulatory developments that could reshape PBM economics. In addition, because Aetna’s medical benefit ratio is a key indicator for cost containment, future quarter results will likely be used to gauge whether improved ratios can persist amid industry-wide utilization inflation.
With the next earnings cycle approaching, the market will also be looking for whether CVS can translate its guidance increases into sustained margins—particularly in areas exposed to policy and reimbursement changes.
